Mymetics announces new collaboration to advance the development of an innovative Malaria vaccine candidate

Mymetics to apply its innovative virosome vaccine technology to develop a transmission-blocking Malaria vaccine candidate

Fully funded by the PATH Malaria Vaccine Initiative (MVI), the study will be developed in partnership with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the NIH

Epalinges, Switzerland, 18 November 2014 – Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that the PATH Malaria Vaccine Initiative (MVI) has chosen Mymetics to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate. MVI is a global program whose objective is to accelerate the development of malaria vaccines and catalyze timely access in endemic countries.
Mymetics' proprietary virosome technology platform and its specialist virosome know-how has been selected to develop an innovative Malaria transmission-blocking vaccine candidate in partnership with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
These new virosome vaccine candidates will each incorporate two different malaria parasite proteins supplied by LMIV and will be then separately tested in  animal studies.
The project will start in November 2014, and preclinical results are expected by early 2016.
If this study is successful, the next step could be to prepare for clinical trials for a malaria transmission-blocking virosome vaccine and also explore the possibilities to combine this vaccine with other malaria vaccine candidates which are focused on other aspects of preventing malaria. Mymetics has shown separately in 2011 in a privately funded Phase 1b clinical trial in Tanzania that a virosome based vaccine for Plasmodium falciparum could reduce malaria episodes in children by more than 50% 1).
According to the World Health Organization, in 2013, 97 countries had ongoing malaria transmission.  There were an estimated 207 million cases of malaria in 2012 and an estimated 627 000 deaths.
About the PATH Malaria Vaccine Initiative (MVI)
The PATH Malaria Vaccine Initiative (MVI) is a global program established at PATH through an initial grant from the Bill & Melinda Gates Foundation. MVI's mission is to accelerate the development of malaria vaccines and catalyze timely access in endemic countries. MVI's vision is a world free from malaria. For more information, please visit
Malaria transmission-blocking vaccine candidates
Transmission-blocking vaccine candidates seek to interrupt the life cycle of the parasite by inducing antibodies that prevent the parasite from maturing in the mosquito after it takes a blood meal from a vaccinated person.
About Laboratory of Malaria Immunology and Vaccinology (LMIV), NIAID
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. LMIV was commissioned in 2009 to conduct basic and applied research relevant to malaria immunology and vaccine development, to pursue novel vaccine concepts, to produce prototype malaria vaccines, and to conduct early-phase clinical trials of promising vaccine candidates. For more information, please visit
About Mymetics
Mymetics Corporation (OTCQB: MYMX) is a Swiss-based biotechnology company registered in the US and trades on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process.
Mymetics develops next-generation preventative vaccines for infectious diseases. Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. The company's vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine.